US 9545451
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
granted A61KA61K39/3955A61K47/68031
Quick answer
US patent 9545451 (Anti-PRLR antibodies and methods for killing PRLR-expressing cells) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K39/3955, A61K47/68031, A61K47/68033, A61K47/6849